Gilead Sciences has made another foray into the natural killer (NK) cell category, paying $300 million upfront to access Dragonfly Therapeutics' TriNKET platform to find therapies for cancer and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback